Compensated Awareness Post View
Disclaimer
InMed Pharmaceuticals, Inc. (IMLFF) Adds to Its Drug Development Pipeline
A pre-clinical stage biopharmaceutical company, InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) has revealed two additions to its drug development pipeline. An expedited drug development timeline is now in place for INM-750 for epidermolysis bullosa (EB), with a potential market of about $1 billion. The disease is characterized by fragile skin in children. The company has also announced the development of INM-085 for glaucoma, which represents a potential global market of over $5 billion.
Resulting in a defect in the connective tissue between the dermis and epidermis, most often caused by a lack of keratins, EB currently has no medication-based treatments. Multiple cannabinoids are the active ingredients of INM-750, which is now under development as a topical drug. These were selected to manage keratin levels in people with EB, in which fragile skin can blister and tear easily with the slightest friction or trauma. The cannabinoids were also chosen to address inflammation, itching, wound healing, pain, and skin regeneration.
One of the leading causes of blindness, glaucoma is associated with high fluid pressure in the eye, which can damage the optic nerve. The first glaucoma treatment of its kind, INM-085 will be a multi-target, multi-mechanism therapy. It will contain multiple cannabinoids that can reduce elevated intra-ocular pressure and protect retinal ganglion cells and optic nerve tissues. The drug will be designed to be applied directly to the eye as a topical formulation.
The new drugs in development are in addition to the company’s other initiatives, including a number of cannabinoid-based drugs. Dr. Ado Muhammed, MD, DPM, MFPM, chief medical officer of IMLFF, is a leader in developing cannabinoid therapies. Prior to joining InMed, he served as executive on board at GW Pharmaceuticals (NASDAQ: GWPH), where he was involved in the development and regulatory approval of one of the first prescription cannabis-based drugs on the market. Muhammed has had strategic roles in the research and development, clinical development, and commercialization of specialty drugs.
InMed’s core assets also include a computer-based drug/disease target screening tool and a proprietary cannabinoid manufacturing system. The bioinformatics tool has helped InMed identify novel cannabinoids thanks to algorithms that have allowed the integration of data from various bioinformatics databases. It also uses a database of approved pharmaceutical products and one consisting of over 90 cannabinoid drugs. The company has used the tool to associate approved pharmaceuticals with cannabinoids that have similar structures in order to identify which ones will act on specific genes and proteins.
A biosynthesis system is in development, which is based on similar processes that use bacteria and yeast in industrial applications. It will allow InMed to manufacture naturally occurring cannabinoids in the laboratory at high yields. An alternative to chemical manufacturing methods, it could address production, quality control, purification, and structural integrity. The system is expected to be a revolution in the rapidly emerging cannabinoid pharmaceutical sector.
For more information, visit the company’s website at www.InMedPharma.com
